IRIDEX - יחס שווי חברה להכנסות IRIX

The promotion of MicroPulse systems for retinal and glaucoma therapy is driving the growth of the mature business, which is reflected in the price action of IRIDEX Corporation (IRIX). The EV/Sales ratio demonstrates the current market valuation, while 366.77 captures a new level. Stability is ensured by the diversification of ophthalmological solutions, and the consumables sales model creates a sustainable cash flow.
IRIX (iridex.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים

To select assets with a high margin of safety, it is critical to evaluate business value without the influence of leverage. This EV/Sales valuation multiple compares the total enterprise value to revenue, allowing the investor to determine if there is an overpayment for the operating sales of IRIDEX Corporation (IRIX) amid the recovery of clinic capital expenditures on ophthalmological lasers in the US and Europe.